Department of Thoracic Surgery, Hubei Cancer Hospital, Wuhan 430079, Hubei Province, PR China.
Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, 210000, Jiangsu Province, PR China.
Biomed Pharmacother. 2018 Jul;103:94-100. doi: 10.1016/j.biopha.2018.03.053. Epub 2018 Apr 7.
Long non-coding RNAs (lncRNAs) have been demonstrated to be involved in the occurrence and progression of multiple cancers. In this study, we investigated the role of the lncRNA DANCR in the development of non-small cell lung cancer (NSCLC). First, we found that DANCR was markedly upregulated in NSCLC tumor tissues and cell lines compared with related normal controls. The ectopic expression of DANCR significantly increased the proliferation, migration and invasion of SPC-A1 and NCL-H1299 cells. Furthermore, we investigated whether DANCR regulates NSCLC tumor formation in vivo. Subsequently, we concluded that DANCR promotes NSCLC cell proliferation, migration and invasion by regulating the tumor suppressor miR-758-3p. These results indicated that the DANCR/miR-758-3p axis could be a potential target in the treatment of NSCLC.
长链非编码 RNA（lncRNA）已被证明参与多种癌症的发生和发展。在这项研究中，我们研究了 lncRNA DANCR 在非小细胞肺癌（NSCLC）发展中的作用。首先，我们发现与相关正常对照相比，DANCR 在 NSCLC 肿瘤组织和细胞系中明显上调。DANCR 的异位表达显著增加了 SPC-A1 和 NCL-H1299 细胞的增殖、迁移和侵袭。此外，我们研究了 DANCR 是否调节体内 NSCLC 肿瘤的形成。随后，我们得出结论，DANCR 通过调节肿瘤抑制因子 miR-758-3p 促进 NSCLC 细胞的增殖、迁移和侵袭。这些结果表明，DANCR/miR-758-3p 轴可能是治疗 NSCLC 的潜在靶点。
